Vishnu Sunil Jaikumar

Uttroside B, a US FDA-designated Orphan drug, mitigates thedevelopment of hepatocellular carcinoma and its pulmonary metastasis via EGFR/ERK-mediated inhibition of SREBP-1 and STAT-3

This study shows that Uttroside B inhibits hepatocellular carcinoma and its pulmonary metastasis by blocking the EGFR/ERK pathway and its downstream targets SREBP-1 and STAT-3.

EPHA2-Ephrin-B1 cis-interaction supports self-renewal ability leading to recurrence of oral cancer.

This study identifies Ephrin-B1-EPHA2 cis-interaction as a driver of oral cancer self-renewal and recurrence, validated through proteomics, biochemical assays, and clinical data.

TIF1γ drives oral cancer recurrence by the transcriptional regulation of self-renewal genes, such as HES1

This study identifies TIF1γ as a driver of oral cancer recurrence by promoting self-renewal through acetylation-dependent regulation of HES1 and other stemness genes.

Uttroside B, a US-FDA-Designated Orphan Drug Against Hepatocellular Carcinoma (HCC), Impedes Non-alcoholic Steatohepatitis (NASH) and NASH -Induced HCC

This study demonstrates that Uttroside B alleviates NASH and prevents its progression to HCC in mouse models.